Fas ligand expression in esophageal carcinomas and their lymph node metastases

Cancer

Volumn 88, Issue 3, 2000, Pages 524-528

  Younes, Mamoun ^a,c   Schwartz, Mary R ^a   Ertan, Atilla ^a   Finnie, Delia ^a   Younes, Anas ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Immunohistochemistry; Metastasis; Squamous cell carcinoma

Indexed keywords

FAS ANTIGEN;

ARTICLE; CANCER INVASION; ESOPHAGUS CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ANTIGENS, CD95; ANTIGENS, SURFACE; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; COLORING AGENTS; ESOPHAGEAL NEOPLASMS; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; LIGANDS; LYMPHATIC METASTASIS; MEMBRANE GLYCOPROTEINS; NEOPLASM INVASIVENESS; PARAFFIN EMBEDDING;

EID: 0034142159     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000201)88:3<524::AID-CNCR5>3.0.CO;2-U     Document Type: Article

References (26)

1. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-56.
2. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/ nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992;267:10709-15.
3. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
4. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
5. Bamberger AM, Schulte HM, Thuneke I, Erdmann I, Bamberger CM, Asa SL. Expression of the apoptosis-inducing Fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab 1997;82: 3173-5.
6. Hunt JS, Vassmer D, Ferguson TA, Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997;158:4122-8.
7. Runic R, Lockwood CJ, Ma Y, Dipasquale B, Guller S. Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. J Clin Endocrinol Metab 1996;81:3119-22.
8. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain. J Clin Invest 1997;99:1173-8.
9. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997;57:1007-12.
10. Gratas C, Tohma Y, Vanmeir EG, Klein M, Tenan M, Ishii N, et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 1997;7:863-9.
11. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997;94: 6420-5.
12. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, et al. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion. Nat Med 1996;2:1361-6.
13. Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A, et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994;57:371-7.
14. Hughes SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A, Iannettoni MD, et al. Fas/Apo-1 (Cd95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 1997;57:5571-8.
15. Chouaib S, Asselinpaturel C, Mamichouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997;18:493-7.
16. Green DR, Ware CF. Fas-ligand: privilege and peril. Proc Natl Acad Sci U S A 1997:94:5986-90.
17. Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997;18:240-4.
18. Nagata S. Fas ligand and immune evasion. Nat Med 1996;2: 1306-7.
19. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (Cd95L) in immune escape: the tumor cell strikes back. J Immunol 1997;158:4521-4.
20. Houghton JA, Harwood FG, Gibson AA, Tillman DM. The Fas signaling pathway is functional in colon carcinoma cells and induces apoptosis. Clin Cancer Res 1997;3:2205-9.
21. Hellquist HB, Olejnicka B, Jadner M, Andersson T, Sederholm C. Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced: a preliminary report. Br J Cancer 1997;76:175-9.
22. Muraki Y, Yoshioka C, Fukuda J, Haneji T, Kobayashi N. Immunohistochemical detection of Fas antigen in oral epithelia. J Oral Pathol Med 1997;26:57-62.
23. Sundelin K, Jadner M, Norbergspaak L, Davidsson A, Hellquist HB. Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue. Eur J Cancer 1997;33:1860-4.
24. Oishi M, Maeda K, Sugiyama S. Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell lines. Arch Dermatol Res 1994;286:396-7.
25. Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and downregulation of Fas expression in human esophageal cancer. Cancer Res 1998;58:2057-62.
26. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998;160:5669-75.